vs

Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and IMPINJ INC (PI). Click either name above to swap in a different company.

IMPINJ INC is the larger business by last-quarter revenue ($74.3M vs $44.9M, roughly 1.7× AbCellera Biologics Inc.). IMPINJ INC runs the higher net margin — 11.2% vs -19.9%, a 31.1% gap on every dollar of revenue. On growth, AbCellera Biologics Inc. posted the faster year-over-year revenue change (788.4% vs -0.0%). IMPINJ INC produced more free cash flow last quarter ($2.2M vs $-44.6M). Over the past eight quarters, AbCellera Biologics Inc.'s revenue compounded faster (112.3% CAGR vs -14.9%).

AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.

Impinj, Inc. is an American manufacturer of radio-frequency identification (RFID) devices and software. The company was founded in 2000 and is headquartered in Seattle, Washington. The company was started based on the research done at the California Institute of Technology by Carver Mead and Chris Diorio. Impinj currently produces EPC Class 1, Gen 2 passive UHF RFID chips, RFID readers, RFID reader chips, and RFID antennas, and software applications for encoding chips, and gathering business ...

ABCL vs PI — Head-to-Head

Bigger by revenue
PI
PI
1.7× larger
PI
$74.3M
$44.9M
ABCL
Growing faster (revenue YoY)
ABCL
ABCL
+788.4% gap
ABCL
788.4%
-0.0%
PI
Higher net margin
PI
PI
31.1% more per $
PI
11.2%
-19.9%
ABCL
More free cash flow
PI
PI
$46.8M more FCF
PI
$2.2M
$-44.6M
ABCL
Faster 2-yr revenue CAGR
ABCL
ABCL
Annualised
ABCL
112.3%
-14.9%
PI

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ABCL
ABCL
PI
PI
Revenue
$44.9M
$74.3M
Net Profit
$-8.9M
$8.3M
Gross Margin
49.1%
Operating Margin
-63.7%
30.5%
Net Margin
-19.9%
11.2%
Revenue YoY
788.4%
-0.0%
Net Profit YoY
73.9%
EPS (diluted)
$-0.03
$0.14

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABCL
ABCL
PI
PI
Q1 26
$74.3M
Q4 25
$44.9M
$92.8M
Q3 25
$9.0M
$96.1M
Q2 25
$17.1M
$97.9M
Q1 25
$4.2M
$74.3M
Q4 24
$5.0M
$91.6M
Q3 24
$6.5M
$95.2M
Q2 24
$7.3M
$102.5M
Net Profit
ABCL
ABCL
PI
PI
Q1 26
$8.3M
Q4 25
$-8.9M
$-1.1M
Q3 25
$-57.1M
$-12.8M
Q2 25
$-34.7M
$11.6M
Q1 25
$-45.6M
$-8.5M
Q4 24
$-2.7M
Q3 24
$-51.1M
$221.0K
Q2 24
$-36.9M
$10.0M
Gross Margin
ABCL
ABCL
PI
PI
Q1 26
49.1%
Q4 25
51.8%
Q3 25
50.3%
Q2 25
57.8%
Q1 25
49.4%
Q4 24
50.5%
Q3 24
50.0%
Q2 24
56.1%
Operating Margin
ABCL
ABCL
PI
PI
Q1 26
30.5%
Q4 25
-63.7%
-2.9%
Q3 25
-851.8%
0.7%
Q2 25
-290.2%
11.1%
Q1 25
-1479.6%
-12.9%
Q4 24
-3.9%
Q3 24
-1439.4%
-0.8%
Q2 24
-1276.2%
8.8%
Net Margin
ABCL
ABCL
PI
PI
Q1 26
11.2%
Q4 25
-19.9%
-1.2%
Q3 25
-637.8%
-13.3%
Q2 25
-203.3%
11.8%
Q1 25
-1077.2%
-11.4%
Q4 24
-2.9%
Q3 24
-785.4%
0.2%
Q2 24
-504.3%
9.7%
EPS (diluted)
ABCL
ABCL
PI
PI
Q1 26
$0.14
Q4 25
$-0.03
$-0.02
Q3 25
$-0.19
$-0.44
Q2 25
$-0.12
$0.39
Q1 25
$-0.15
$-0.30
Q4 24
$-0.06
Q3 24
$-0.17
$0.01
Q2 24
$-0.13
$0.34

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABCL
ABCL
PI
PI
Cash + ST InvestmentsLiquidity on hand
$128.5M
$131.8M
Total DebtLower is stronger
$241.5M
Stockholders' EquityBook value
$966.9M
Total Assets
$1.4B
$502.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABCL
ABCL
PI
PI
Q1 26
$131.8M
Q4 25
$128.5M
$175.3M
Q3 25
$83.2M
$190.1M
Q2 25
$92.4M
$193.2M
Q1 25
$159.3M
$147.9M
Q4 24
$156.3M
$164.7M
Q3 24
$126.6M
$170.3M
Q2 24
$148.3M
$220.2M
Total Debt
ABCL
ABCL
PI
PI
Q1 26
$241.5M
Q4 25
$280.9M
Q3 25
$280.4M
Q2 25
Q1 25
Q4 24
$283.5M
Q3 24
Q2 24
Stockholders' Equity
ABCL
ABCL
PI
PI
Q1 26
Q4 25
$966.9M
$209.2M
Q3 25
$964.0M
$195.0M
Q2 25
$1.0B
$187.7M
Q1 25
$1.0B
$160.6M
Q4 24
$1.1B
$149.9M
Q3 24
$1.1B
$136.1M
Q2 24
$1.1B
$117.0M
Total Assets
ABCL
ABCL
PI
PI
Q1 26
$502.5M
Q4 25
$1.4B
$545.2M
Q3 25
$1.4B
$516.5M
Q2 25
$1.4B
$508.8M
Q1 25
$1.3B
$479.8M
Q4 24
$1.4B
$489.1M
Q3 24
$1.4B
$476.4M
Q2 24
$1.4B
$446.1M
Debt / Equity
ABCL
ABCL
PI
PI
Q1 26
Q4 25
1.34×
Q3 25
1.44×
Q2 25
Q1 25
Q4 24
1.89×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABCL
ABCL
PI
PI
Operating Cash FlowLast quarter
$-34.7M
Free Cash FlowOCF − Capex
$-44.6M
$2.2M
FCF MarginFCF / Revenue
-99.4%
3.0%
Capex IntensityCapex / Revenue
21.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-174.1M
$61.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABCL
ABCL
PI
PI
Q1 26
Q4 25
$-34.7M
$15.1M
Q3 25
$-52.6M
$20.9M
Q2 25
$-32.4M
$33.9M
Q1 25
$-11.6M
$-11.1M
Q4 24
$-108.6M
$12.6M
Q3 24
$-28.9M
$10.1M
Q2 24
$-30.0M
$45.5M
Free Cash Flow
ABCL
ABCL
PI
PI
Q1 26
$2.2M
Q4 25
$-44.6M
$13.6M
Q3 25
$-61.5M
$18.0M
Q2 25
$-45.8M
$27.3M
Q1 25
$-22.2M
$-13.0M
Q4 24
$-187.0M
$8.5M
Q3 24
$-47.4M
$4.7M
Q2 24
$-50.1M
$44.1M
FCF Margin
ABCL
ABCL
PI
PI
Q1 26
3.0%
Q4 25
-99.4%
14.7%
Q3 25
-687.0%
18.7%
Q2 25
-267.9%
27.9%
Q1 25
-524.0%
-17.5%
Q4 24
-3702.8%
9.3%
Q3 24
-728.4%
4.9%
Q2 24
-683.8%
43.0%
Capex Intensity
ABCL
ABCL
PI
PI
Q1 26
Q4 25
21.9%
1.6%
Q3 25
99.7%
3.1%
Q2 25
78.2%
6.7%
Q1 25
251.1%
2.5%
Q4 24
1552.7%
4.5%
Q3 24
284.6%
5.7%
Q2 24
274.6%
1.3%
Cash Conversion
ABCL
ABCL
PI
PI
Q1 26
Q4 25
Q3 25
Q2 25
2.93×
Q1 25
Q4 24
Q3 24
45.56×
Q2 24
4.56×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons